A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD)

Key Inclusion Criteria:

• Male or female aged ≥ 18 and < 75 years.

• Moderate-to-severe AD.

• Documented history of inadequate response or lack of tolerability to a stableregimen of one or more topical treatment before the Screening visit, or for whomtopical treatments are otherwise inadvisable.

• Female participants who are not pregnant or breastfeeding and meet at least one ofthe following conditions: not of childbearing potential or of childbearing potentialand agrees to use a highly effective method of contraception.

Key Exclusion Criteria:

• Known hepatitis B, hepatitis C, or human immunodeficiency virus infection.

• Evidence of active or latent tuberculosis (TB).

• History of untreated or inadequately treated TB infection.

• Active infection requiring treatment with systemic antibiotics, antivirals,antifungals, antiparasitics or antiprotozoals at the Screening visit.

• Active unstable pruritic skin conditions in addition to AD that would interfere withthe assessment of AD based on the investigator's clinical judgement.

• Other conditions or laboratory abnormality that could increase the risk associatedwith study participation or could interfere with the interpretation of study resultsand, in the judgment of the investigator, would make the patient inappropriate forentry into the study.